Exceptional Access Program for use of VENCLEXTA®(venetoclax) monotherapy in treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Latest Information Update: 28 May 2019
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 28 May 2019 New trial record
- 23 May 2019 According to an AbbVie Media release, the company signed an agreement with pan-Canadian Pharmaceutical Alliance(pCPA) and announced that Ontario is the first province to reimburse VENCLEXTA(venetoclax) monotherapy under its Drugs and Devices Division's (DDD) Exceptional Access Program for patients with chronic lymphocytic leukemia(CLL).